Systemic treatment in advanced soft tissue sarcoma: What is standard, what is new

Research output: Contribution to journalShort surveypeer-review


For metastatic soft tissue sarcoma (STS) patients not eligible for surgery, systemic treatments, including standard chemotherapy and newer biological compounds, still play the most relevant role in the management of the disease. An anthracycline and alkylating agent combination has formed the cornerstone of chemotherapy in STS for more than 30 years, with its value over that of administration of anthracycline as a single agent still being debated. Efforts have been made to improve the activity and minimise the toxicity of the combination, as well as to explore the upfront efficacy of agents known to be active in sarcoma and to develop new biological compounds. Nevertheless, beyond the first line, evidence for medical treatment in STS is less robust and all the more driven by histology. Thus, the introduction of kinases and small molecule inhibitors in the treatment armamentarium for STS is a major achievement in this setting. Preliminary data on immunotherapy are also available and discussed in this review.

Original languageEnglish
Article number109
JournalBMC Medicine
Issue number1
Publication statusPublished - Jun 2 2017


  • Advanced sarcoma
  • Chemotherapy
  • Immunotherapy
  • Metastatic sarcoma
  • Sarcoma
  • Survival
  • Tyrosine kinase inhibitors
  • VEGF inhibitors

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Systemic treatment in advanced soft tissue sarcoma: What is standard, what is new'. Together they form a unique fingerprint.

Cite this